Records containing: Herpes Zoster
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2017-09-26An Open-label, Single-arm, Phase IV Study Assessing the Immunogenicity and Safety of ZOSTAVAX® at Minimum Release Specification Approaching Expiry Potency in Subjects ≥50 Years Old.
-
CLINICAL_TRIALS study record update · 2017-08-04A Comparative Study of Tzanck Smear With Methylene Blue Versus Giemsa Stain to Diagnose Herpes Simplex, Herpes Zoster and Varicella Zoster Skin Infections
-
CLINICAL_TRIALS study record update · 2017-07-19Placebo Controlled Evaluation of the Cell Mediated Immune Response of Cirrhotic Subjects to Zostavax™
-
CLINICAL_TRIALS study record update · 2017-07-05Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older
-
CLINICAL_TRIALS study record update · 2017-06-07Safety and Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A in Adult HIV-infected Subjects
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2017-05-25Study to Evaluate Safety and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults Aged 18 Years and Older With Haematologic Malignancies
-
CLINICAL_TRIALS study record update · 2017-05-24Consistency, Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults 50 Years of Age or Older
-
CLINICAL_TRIALS study record update · 2017-05-01Efficacy, Safety, and Immunogenicity Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults Aged 50 Years or Older
-
CLINICAL_TRIALS study record update · 2017-04-19Effect of Early Use of Oxycodone During the Acute Phase of Herpes Zoster on Preventing Postherpetic Neuralgia
-
CLINICAL_TRIALS study record update · 2017-04-19A Randomized, Double Blinded, Multi-center Phase III Confirmatory Study to Assess the Immunogenicity and Safety of NBP608 Compared to Zostavax in Healthy Adult Aged 50 and Over
-
CLINICAL_TRIALS study record update · 2017-04-17A Multi-center, Randomized, Double Blinded, Parallel-group Study to Assess the Immunogenicity and Safety of NBP608 Compared to Zostavax in Healthy Adult Aged 50 and Over
-
CLINICAL_TRIALS study record update · 2017-03-31Open-label Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults Aged 50 Years or Older
-
CLINICAL_TRIALS study record update · 2017-03-07Immunogenicity and Safety of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults With a Prior Episode of Herpes Zoster
-
CLINICAL_TRIALS study record update · 2017-03-03T Cell Responses to Varicella Zoster Virus After Vaccination and Viral Escape
-
CLINICAL_TRIALS study record update · 2017-02-14A Phase III, Double-Blind, Randomized, Multicenter Study to Evaluate the Immunogenicity, Safety, and Tolerability of ZOSTAVAX™ Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated)
-
CLINICAL_TRIALS study record update · 2017-01-09Phase I Trial of ZOSTAVAX® Prior to Renal Transplantation
-
CLINICAL_TRIALS study record update · 2017-01-06Safety and Immunogenicity Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A When Administered Subcutaneously Versus Intramuscularly in Adults Aged 50 Years or Older
-
CLINICAL_TRIALS study record update · 2016-08-15ClinicalTrials.gov study NCT02526745
-
CLINICAL_TRIALS study record update · 2016-08-02A Double-Blind, Placebo-Controlled Single Dose Escalating Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP2151 in Healthy Male Subjects, Followed by an Open, Two-Period Crossover Study to Assess the Effect of Fed Conditions on the Safety, Tolerability and Pharmacokinetics of ASP2151
-
CLINICAL_TRIALS study record update · 2016-07-14Herpes Zoster Prevalence in Frailty Consultations in University Hospital of Toulouse
-
CLINICAL_TRIALS study record update · 2016-02-10Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults Aged 50 Years and Older
-
CLINICAL_TRIALS study record update · 2015-10-12A Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Comparative Study of FV-100 vs. Valacyclovir in Patients With Herpes Zoster
-
CLINICAL_TRIALS study record update · 2015-09-28Population Based Surveillance to Estimate the Burden of Herpes Zoster and Postherpetic Neuralgia in Spain
-
CLINICAL_TRIALS study record update · 2015-09-23Measuring Herpes Zoster and Post-Herpetic Neuralgia Associated Burden of Illness and Health Care Utilization and Costs in Thailand
-
CLINICAL_TRIALS study record update · 2015-08-13A Phase III, Double-Blind, Lot-To-Lot Consistency Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of V212 in Healthy Adults